Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you consider eliminating post lumpectomy RT in a premenopausal patient with pCR after chemotherapy for a cT1cN0 triple negative breast cancer?
Answer from: Radiation Oncologist at Community Practice
We don't have any prospective data on omitting RT in this case and would not consider this approach for triple negative patients.
Sign in or Register to read more
12900
Related Questions
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
With the presentation of HypoG-01 phase III UNICANCER trial at ESMO 2024, should hypofractionated radiotherapy be the standard across the board for breast cancer?
Would you offer prone APBI with IMRT/VMAT?
What are your top takeaways in Breast Cancer from ESMO 2024?
When should the dissected axilla (levels I-II) be included when delivering RNI?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
Do you recommend re-excision of a unifocal positive anterior margin at skin after lumpectomy in a patient with otherwise low risk breast cancer features?
How would you approach an isolated supraclavicular nodal recurrence involving the skin in a patient who has received standard chest wall and nodal radiation therapy?
What are the advantages/disadvantages of using static IMRT vs VMAT when treating breast cancer?
Would you recommend PMRT to a clinically node positive (biopsy proven axillary node and indeterminate single IMN node) BRCA positive patient with multiple medical co-morbidities including scleroderma and ILD who is treated with neoadjuvant chemotherapy (NAC) and mastectomy who converts to ypT0/ypN0?